Top CAR T-Cell Therapy Companies

The increasing incidence of hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma, is a major driver of the CAR T-cell therapy market. Traditional treatments, including chemotherapy and radiation, often fail to provide long-term remission, leaving patients with limited options. CAR T-cell therapy addresses this unmet clinical need by genetically modifying a patient’s own T-cells to recognize and destroy cancer cells, offering targeted and durable responses. As awareness of this therapy grows among oncologists and patients, coupled with the global rise in cancer prevalence, demand for CAR T-cell treatments continues to accelerate.

Industry Overview

According to SkyQuest Technology “Medical CAR T-Cell Therapy Market” By Product (Yescarta, Kymriah), By Target (CD19, BCMA) By Indication, By End User, By Region - Industry Forecast 2025-2032,” Global CAR T-cell therapy market is projected to grow at a CAGR of over 38.2% by 2032, on account of urgent need for automating quantified data. Technological innovations in gene-editing, viral vector engineering, and automated cell-manufacturing processes are key factors driving CAR T-cell therapy adoption. Enhanced techniques, such as CRISPR and next-generation viral vectors, improve the precision and safety of genetically modified T-cells, reducing off-target effects and severe side effects.

Top 10 Global CAR T-Cell Therapy Companies

1. Bluebird Bio

Bluebird Bio is a global biotechnology company focused on developing innovative gene and cell therapies to treat severe genetic diseases and cancer. Founded in 1992 and headquartered in Cambridge, Massachusetts, the company has established itself as a leader in gene editing and CAR T-cell therapy. Its core offerings include gene therapies for conditions such as sickle cell disease and cerebral adrenoleukodystrophy, along with CAR T-cell therapies targeting hematologic malignancies. Bluebird Bio continues to expand its pipeline through research collaborations and strategic partnerships, driving innovation in advanced therapeutics.

2. Medigene AG

Medigene AG is a Germany-based biotechnology company specializing in the development of innovative T cell-based immunotherapies for cancer treatment. Founded in 1997 and headquartered in Martinsried, the company focuses on TCR-T cell therapies, co-stimulatory switch proteins, and immuno-oncology platforms. Medigene conducts extensive clinical trials targeting both solid tumors and hematologic malignancies, aiming to deliver safe and effective treatments. Through strategic collaborations and partnerships with academic and industry leaders, Medigene AG continues to advance its pipeline, solidifying its position as a pioneering force in precision immunotherapy and cellular therapy innovation.

3. Atara Biotherapeutics

Atara Biotherapeutics is a global biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and autoimmune diseases. Founded in 2012 and headquartered in South San Francisco, California, the company specializes in off-the-shelf EBV-targeted T-cell therapies and innovative pipeline programs. Its core offerings include treatments for hematologic malignancies, solid tumors, and autoimmune conditions. Atara Biotherapeutics advances its research through clinical trials, strategic collaborations, and manufacturing innovations, aiming to provide safe, effective, and scalable therapies. The company continues to expand its presence in the cellular therapy and immuno-oncology landscape.

4. Gilead Sciences

Gilead Sciences is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has grown into a leader in antiviral treatments, oncology, and cellular therapies, including CAR T-cell research. Its core offerings span HIV, hepatitis, and oncology treatments, with ongoing advancements in gene and cell therapy pipelines. Through strategic acquisitions, research collaborations, and clinical trials, Gilead continues to expand its impact on global healthcare, driving innovation and delivering transformative therapies to patients worldwide.

5. Celyad Oncology

Celyad Oncology is a global biopharmaceutical company focused on developing innovative allogeneic CAR T-cell therapies for cancer treatment. Founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, the company specializes in engineered T-cell therapies designed to target hematologic malignancies and solid tumors. Its core offerings include advanced CAR T-cell platforms and proprietary technology for enhancing safety and efficacy. Celyad Oncology advances its pipeline through rigorous clinical trials, strategic collaborations, and manufacturing innovations, aiming to deliver accessible, effective, and next-generation immunotherapies that transform the standard of care in oncology worldwide.

6. Juno Therapeutics

Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, is a global biopharmaceutical company focused on developing innovative CAR T-cell therapies for blood cancers. Founded in 2013 and headquartered in Seattle, Washington, the company specializes in engineered T-cell therapies designed to provide targeted, durable responses in hematologic malignancies. Its core offerings include CAR T-cell platforms, clinical development programs, and pipeline therapies for leukemia and lymphoma. Juno Therapeutics advances its mission through strategic partnerships, research collaborations, and clinical trials, driving innovation in cellular immunotherapy and improving outcomes for patients worldwide.

7. Legend Biotech

Legend Biotech is a global biopharmaceutical company dedicated to developing innovative CAR T-cell therapies for cancer treatment. Founded in 2014 and headquartered in Nanjing, China, the company focuses on targeted therapies for multiple myeloma and other hematologic malignancies. Its core offerings include advanced CAR T-cell platforms, clinical development programs, and a robust research pipeline. Legend Biotech advances its mission through strategic collaborations, global clinical trials, and manufacturing innovations, aiming to provide safe, effective, and accessible cell therapies that transform cancer treatment and improve patient outcomes worldwide.

8. Autolus Therapeutics

Autolus Therapeutics is a global biopharmaceutical company focused on developing next-generation autologous T-cell therapies for cancer treatment. Founded in 2014 and headquartered in London, UK, the company specializes in engineered T-cell platforms designed to provide targeted, durable responses in hematologic malignancies and solid tumors. Its core offerings include CAR T-cell therapies, cell programming technologies, and a robust clinical development pipeline. Autolus advances its mission through strategic collaborations, innovative manufacturing processes, and global clinical trials, aiming to deliver safe, effective, and accessible cellular immunotherapies that improve patient outcomes worldwide.

9. Kite Pharma

Kite Pharma, a subsidiary of Gilead Sciences, is a global biopharmaceutical company specializing in the development of innovative CAR T-cell therapies for cancer treatment. Founded in 2009 and headquartered in Santa Monica, California, the company focuses on engineered T-cell platforms designed to treat hematologic malignancies and solid tumors. Its core offerings include CAR T-cell therapies, clinical development programs, and advanced manufacturing capabilities. Kite Pharma drives innovation through global clinical trials, strategic collaborations, and research initiatives, aiming to deliver safe, effective, and accessible cellular immunotherapies that transform cancer care worldwide.

10. Poseida Therapeutics

Poseida Therapeutics is a global biopharmaceutical company focused on developing innovative allogeneic CAR T-cell therapies and gene therapies for cancer and other serious diseases. Founded in 2014 and headquartered in San Diego, California, the company specializes in engineered T-cell platforms designed to provide targeted, durable, and scalable treatment options. Its core offerings include CAR T-cell therapies, gene editing technologies, clinical development programs, and manufacturing innovations. Poseida Therapeutics advances its mission through strategic collaborations, global clinical trials, and research initiatives, aiming to deliver safe, effective, and accessible cellular immunotherapies worldwide.

Other Leading Global CAR T-Cell Therapy Companies

• Cellectis
• CellDesign Labs
• Novartis Pharmaceuticals
• Sorrento Therapeutics
• Bellicum Pharmaceuticals
• Gracell Biotechnologies
• TC BioPharm
• Xyphos Biosciences
• Carina Biotech
• Bristol-Myers Squibb

Conclusion

The Global CAR T-Cell Therapy Market is experiencing rapid growth driven by the rising incidence of hematologic malignancies and the limitations of conventional treatments like chemotherapy and radiation. CAR T-cell therapy offers targeted, durable, and personalized treatment options, addressing unmet clinical needs and improving patient outcomes. Technological innovations in gene editing, viral vectors, and automated cell manufacturing, including CRISPR and next-generation platforms, are enhancing therapy precision and safety. Leading biopharmaceutical companies are expanding pipelines, forming strategic collaborations, and advancing clinical trials, collectively propelling market adoption. As awareness and accessibility increase, CAR T-cell therapy demand continues to accelerate globally.